glp-1 and satiety Frontiers GLP-1 Agonist: The Good, the

In the Step 1 trial (note: funded by Novo-Nordisk) of 1,961 individuals, the average weight loss at 68 weeks was 14.9% at the maximum dose of 2.4 mg weekly, equating to 15.3 kg (33.6 lbs) lost compared to 2.6 kg (5.7 lbs) in the placebo group

This latest study suggests semaglutide may also improve taste sensitivity in adults with obesity, especially for sweet tastes, but more research is needed to confirm these findings

Add a small note: Evidence varies by route, formulation, and study context. Use a clinical editorial style with no human before-and-after imagery, no syringes, no dosing instructions, no product packaging, and no guaranteed outcome claims.

Most of the studies with Ceramide AP test it as part of a multi-ceramide complex